- Home
- OVID vs ATRA Comparison
OVID vs ATRA Comparison
Compare OVID & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | ATRA |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 129.4M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OVID | ATRA |
|---|---|---|
| Price | $1.67 | $17.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.50 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.5M | 75.8K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.97 |
| Revenue | $6,610,000.00 | ★ $151,930,000.00 |
| Revenue This Year | $1,077.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.20 |
| Revenue Growth | ★ 945.89 | 51.27 |
| 52 Week Low | $0.24 | $5.01 |
| 52 Week High | $2.01 | $18.95 |
Technical Indicators
Market Signals| Indicator | OVID | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 63.24 |
| Support Level | $1.59 | $16.59 |
| Resistance Level | $1.88 | $18.30 |
| Average True Range (ATR) | 0.12 | 1.20 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 66.13 | 61.53 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).